Navigation Links
AstraZeneca Outlines Principles for Product-Related Online Communications
Date:3/1/2010

WILMINGTON, Del., March 1 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today asked the U.S. Food and Drug Administration (FDA) to adopt guidance that will enable AstraZeneca and others to fully engage in real-time, social media conversations that responsibly provide accurate, balanced information on medicines from a known, identifiable and reliable source.  

(Logo:  http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

AstraZeneca's proposal was in response to the FDA's September 2009 Call for Comments on their public notice: Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools.

"AstraZeneca understands the value of social media to engage key stakeholders in today's technology-driven world," said Bob Perkins, Vice President, Public Policy and Promotional Affairs. "While we have developed a corporate presence in the digital space, we believe it is increasingly important to participate in online channels to provide accurate and regulated information about our branded products in conversations with patients, caregivers, and health care providers."

AstraZeneca believes that five principles should be at the core of any company engagement in social media:

  • Truth and Accuracy: Content must be created, developed, or made available that is truthful, balanced, accurate, and not misleading.

  • To Be Respectful:  Encourage product sponsor participation that respects the interests of patients, caregivers, and health care providers, particularly related to matters of privacy and the primacy of the patient/physician relationship.

  • Protect and Advance Patient Health: Facilitate patient access to quality information for use with their physician to improve their health and protect patients through encouraging accurate and timely reporting on medicine safety.

  • Transparency: Any product sponsor participation should be accomplished in a manner that, at all times, is entirely transparent to other participants as to the role of product sponsors as participants in online discussion.

  • Respect the Views of Others: Acknowledge that patients, caregivers, clinicians and others who participate in social media have their own opinions and that, when they differ from those of the product sponsor, it is not the role of a product sponsor to censor or limit these views but to add the product sponsor's own views to the discussion.

In its comments to the FDA, AstraZeneca proposed a regulatory framework that is consistent with these principles and defines, distinguishes, and distinctly regulates three types of communications on the Internet and in social media:

  • Company-controlled, hosted online communications  

  • Company-controlled communications  

  • Real-time, social media participation communications

The company also noted that, "Without guidance, our activities are limited in a manner that we believe is not in the best interests of informed health care decision making.  In our absence, consumers will turn to information sources that are not regulated and not always well informed."

AstraZeneca believes the company has an obligation to participate in social media in a responsible way to help educate and empower patients, caregivers and prescribers to make informed decisions about its products.

Click here to view AstraZeneca's full submission: http://www.astrazeneca-us.com/_mshost795281/content/media/FDA-2009-N-0441.pdf

NOTES TO EDITORS:

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  In the United States, AstraZeneca is a $14.8 billion healthcare business.

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

SOURCE AstraZeneca

Back to top

RELATED LINKS
http://www.astrazeneca-us.com

'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
2. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
3. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
4. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
5. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
8. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
9. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
10. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
11. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 2016 /PRNewswire/ -  Equicare Health Inc ., the leading ... as one of the top 100 companies in the ... that distinguishes the top digital health companies across the ... forward this year continually upgrading our product with the ... and team," says Len Grenier , CEO of ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
(Date:11/30/2016)... GREENWICH, Connecticut , November 30, 2016 ...   ... Aptuit, LLC today announced ... screening library. An additional 150,000 novel compounds have increased the ... selected to broaden the hit discovery capabilities of the company. ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... SSCI, the ... to discuss the implications of the latest FDA guidance on pharmaceutical cocrystals as ... 2016 in Cambridge, MA. , The event follows the successful November 15th ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by ... Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region - ... grow from USD 10.74 Billion in 2015 to reach USD 32.73 Billion ... Continue Reading ... ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
Breaking Biology News(10 mins):